Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Temporal stability and prognostic biomarker potential of the prostate cancer urine transcriptome.

Jeon J, Olkhov-Mitsel E, Xie H, Yao CQ, Zhao F, Jahangiri S, Cuizon C, Scarcello S, Jeyapala R, Watson JD, Fraser M, Ray J, Commisso K, Loblaw A, Fleshner NE, Bristow RG, Downes M, Vesprini D, Liu S, Bapat B, Boutros PC.

J Natl Cancer Inst. 2019 Jun 4. pii: djz112. doi: 10.1093/jnci/djz112. [Epub ahead of print]

PMID:
31161221
2.

Reply by Authors.

Richard PO, Bashir S, Riverin BD, Alibhai SMH, Kim SJ, Ahmad A, Fleshner NE, Gupta A, Mohammed A, Zlotta AR, Kulkarni GS.

J Urol. 2019 Aug;202(2):325. doi: 10.1097/01.JU.0000558494.56102.db. Epub 2019 Jul 8. No abstract available.

PMID:
31042130
3.

Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?

Wettstein MS, Rooprai JK, Pazhepurackel C, Wallis CJD, Klaassen Z, Uleryk EM, Hermanns T, Fleshner NE, Zlotta AR, Kulkarni GS.

PLoS One. 2019 Apr 29;14(4):e0216255. doi: 10.1371/journal.pone.0216255. eCollection 2019.

4.

An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.

Longo J, Mullen PJ, Yu R, van Leeuwen JE, Masoomian M, Woon DTS, Wang Y, Chen EX, Hamilton RJ, Sweet JM, van der Kwast TH, Fleshner NE, Penn LZ.

Mol Metab. 2019 Jul;25:119-130. doi: 10.1016/j.molmet.2019.04.003. Epub 2019 Apr 10.

5.

Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.

Kamdar S, Isserlin R, Van der Kwast T, Zlotta AR, Bader GD, Fleshner NE, Bapat B.

Clin Epigenetics. 2019 Mar 27;11(1):54. doi: 10.1186/s13148-019-0651-z.

6.

Pfilates and Hypopressives for the Treatment of Urinary Incontinence After Radical Prostatectomy: Results of a Feasibility Randomized Controlled Trial.

Au D, Matthew AG, Alibhai SMH, Jones JM, Fleshner NE, Finelli A, Elterman D, Singal RK, Jamnicky L, Faghani N, Hilton WJ, Auger LE, Ritvo P, Trachtenberg J, Santa Mina D.

PM R. 2019 Mar 14. doi: 10.1002/pmrj.12157. [Epub ahead of print]

PMID:
30873696
7.

Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population Based Study.

Richard PO, Bashir S, Riverin BD, Alibhai SMH, Kim SJ, Ahmad A, Fleshner NE, Gupta A, Mohammed A, Zlotta AR, Kulkarni GS.

J Urol. 2019 Aug;202(2):319-325. doi: 10.1097/JU.0000000000000213. Epub 2019 Jul 8.

PMID:
30865566
8.

Population-based outcomes of men with a single negative prostate biopsy: Importance of continued follow-up among older patients.

Sayyid RK, Alibhai SMH, Sutradhar R, Eberg M, Fung K, Klaassen Z, Goldberg H, Perlis N, Madi R, Terris MK, Urbach DR, Fleshner NE.

Urol Oncol. 2019 May;37(5):298.e19-298.e27. doi: 10.1016/j.urolonc.2019.01.030. Epub 2019 Feb 13.

PMID:
30770299
9.

Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.

Jiang DM, Jiang H, Chung PWM, Zlotta AR, Fleshner NE, Bristow RG, Berlin A, Kulkarni GS, Alimohamed NS, Lo G, Sridhar SS.

Clin Genitourin Cancer. 2019 Feb;17(1):38-45. doi: 10.1016/j.clgc.2018.09.021. Epub 2018 Oct 4.

PMID:
30686350
10.

A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes.

Glicksman R, Sanmamed N, Thoms J, Zlotta AR, Finelli A, van der Kwast T, Sweet J, Jewett M, Klotz LH, Rosewall T, Fleshner NE, Bristow RG, Warde P, Berlin A.

Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):61-66. doi: 10.1016/j.ijrobp.2018.12.054. Epub 2019 Jan 6.

PMID:
30625410
11.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2019 Feb;51(2):363. doi: 10.1038/s41588-018-0330-6.

PMID:
30622367
12.

The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity.

Chandrasekar T, Goldberg H, Klaassen Z, Wallis CJD, Woon DTS, Herrera-Caceres JO, Kulkarni GS, Fleshner NE.

Cancer. 2019 Apr 1;125(7):1050-1059. doi: 10.1002/cncr.31916. Epub 2018 Dec 18.

PMID:
30561782
13.

Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer-The Forgotten Dance Partner?

Klaassen Z, Wallis CJD, Fleshner NE.

JAMA Oncol. 2018 Nov 29. doi: 10.1001/jamaoncol.2018.5191. [Epub ahead of print] No abstract available.

PMID:
30489621
14.

The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation.

Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, Squire JA, Latour M, Trudel D, Mes-Masson AM, Saad F.

BMC Urol. 2018 Sep 10;18(1):78. doi: 10.1186/s12894-018-0392-x.

15.

International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.

Berlin A, Moraes FY, Sanmamed N, Glicksman R, Koven A, Espin-Garcia O, Leite ETT, Silva JLF, Gadia R, Nesbitt M, Catton CN, Kaffenberger S, Salami SS, Morgan TM, Hearn JWD, Jackson WC, Mehra R, Chung P, Fleshner NE, Zumsteg ZS, Dess RT, Feng FY, Finelli A, Spratt DE.

J Urol. 2019 Feb;201(2):284-291. doi: 10.1016/j.juro.2018.08.044.

PMID:
30153435
16.

The association between physician trust and prostate-specific antigen screening: Implications for shared decision-making.

Klaassen Z, Wallis CJD, Goldberg H, Chandrasekar T, Fleshner NE, Finelli A, Kulkarni GS, Detsky AS, Satkunasivam R.

Can Urol Assoc J. 2018 Jun 19. doi: 10.5489/cuaj.5351. [Epub ahead of print]

17.

The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres.

Saad F, Fleshner NE, So A, Le Lorier J, Perrault L, Poulin-Costello M, Rogoza R, Robson EJD.

Can Urol Assoc J. 2018 Jun 19. doi: 10.5489/cuaj.5053. [Epub ahead of print]

18.

Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial.

Santa Mina D, Hilton WJ, Matthew AG, Awasthi R, Bousquet-Dion G, Alibhai SMH, Au D, Fleshner NE, Finelli A, Clarke H, Aprikian A, Tanguay S, Carli F.

Surg Oncol. 2018 Jun;27(2):289-298. doi: 10.1016/j.suronc.2018.05.010. Epub 2018 May 7.

PMID:
29937184
19.

Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer.

Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y.

Cancer Med. 2018 Jun 14. doi: 10.1002/cam4.1587. [Epub ahead of print]

20.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants.

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger G, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Hakansson N, West C, Dunning AM, Burnet N, Mucci L, Giovannucci E, Andriole G, Cussenot O, Cancel-Tassin G, Koutros S, Freeman LEB, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein B, Kerns S, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Fachal L, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weisher M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Slavov C, Mitev V, Parliament M, Singhal S, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Kierzek A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Kraft P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Freedman M, Wiklund F, Chanock S, Henderson BE, Easton DF, Haiman CA, Eeles RA, Conti DV, Kote-Jarai Z.

Nat Commun. 2018 Jun 11;9(1):2256. doi: 10.1038/s41467-018-04109-8.

21.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Gago-Dominguez M, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA; Profile Study; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11. Erratum in: Nat Genet. 2019 Feb;51(2):363.

22.

Statin use and time to progression in men on active surveillance for prostate cancer.

Jayalath VH, Nayan M, Finelli A, Komisarenki M, Timilshina N, Kulkarni GS, Fleshner NE, Bhindi B, Evans A, Zlotta AR, Hamilton RJ.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):509-515. doi: 10.1038/s41391-018-0053-x. Epub 2018 Jun 6.

PMID:
29875433
23.

Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis.

Goldberg H, Klaassen Z, Chandrasekar T, Sayyid R, Kulkarni GS, Hamilton RJ, Fleshner NE.

Oncotarget. 2018 Apr 10;9(27):18797-18810. doi: 10.18632/oncotarget.24694. eCollection 2018 Apr 10.

24.

High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis.

Chandrasekar T, Klaassen Z, Goldberg H, Sayyid RK, Kulkarni GS, Fleshner NE.

Oncotarget. 2018 Mar 30;9(24):16731-16743. doi: 10.18632/oncotarget.24675. eCollection 2018 Mar 30.

25.

A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores.

Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, Aprikian AG, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, Karakiewicz PI.

Pathol Oncol Res. 2019 Jul;25(3):979-986. doi: 10.1007/s12253-018-0408-6. Epub 2018 Apr 6.

PMID:
29623528
26.

Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A populationbased analysis.

Richard PO, Ahmad AE, Bashir S, Zlotta A, Bhindi B, Leao R, Nayan M, Mohammed A, Fleshner NE, Kulkarni GS.

Can Urol Assoc J. 2018 Jun;12(6):203-210. doi: 10.5489/cuaj.4870. Epub 2018 Feb 23.

27.

Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.

Westhoff E, Witjes JA, Fleshner NE, Lerner SP, Shariat SF, Steineck G, Kampman E, Kiemeney LA, Vrieling A.

Bladder Cancer. 2018 Jan 20;4(1):91-112. doi: 10.3233/BLC-170147.

29.

Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives.

Sayyid RK, Sayyid AK, Klaassen Z, Hersey K, Goldberg H, Perlis N, Ahmad A, Leao R, Chandrasekar T, Fadaak K, Madi R, Terris MK, Finelli A, Hamilton RJ, Kulkarni GS, Zlotta AR, Fleshner NE.

Can Urol Assoc J. 2018 May;12(5):E210-E218. doi: 10.5489/cuaj.4922. Epub 2018 Feb 6.

30.

Changing Trends for Suicidal Death in Patients With Bladder Cancer: A 40+ Year Population-level Analysis.

Klaassen Z, Goldberg H, Chandrasekar T, Arora K, Sayyid RK, Hamilton RJ, Fleshner NE, Williams SB, Wallis CJD, Kulkarni GS.

Clin Genitourin Cancer. 2018 Jun;16(3):206-212.e1. doi: 10.1016/j.clgc.2017.12.016. Epub 2018 Jan 5.

PMID:
29395948
31.

Assessment of Serum microRNA Biomarkers to Predict Reclassification of Prostate Cancer in Patients on Active Surveillance.

Liu RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, Commisso K, Klotz L, Loblaw A, Liu SK, Vesprini D, Fleshner NE, Bapat B.

J Urol. 2018 Jun;199(6):1475-1481. doi: 10.1016/j.juro.2017.12.006. Epub 2017 Dec 12.

PMID:
29246734
32.

Extended Venous Thromboembolism Prophylaxis after Radical Cystectomy: A Call for Adherence to Current Guidelines.

Klaassen Z, Arora K, Goldberg H, Chandrasekar T, Wallis CJD, Sayyid RK, Fleshner NE, Finelli A, Kutikov A, Violette PD, Kulkarni GS.

J Urol. 2018 Apr;199(4):906-914. doi: 10.1016/j.juro.2017.08.130. Epub 2017 Nov 4. Review.

PMID:
29113840
33.

Lymphadenectomy in Gleason 7 prostate cancer: Adherence to guidelines and effect on clinical outcomes.

Chandrasekar T, Goldberg H, Klaassen Z, Sayyid RK, Hamilton RJ, Fleshner NE, Kulkarni GS.

Urol Oncol. 2018 Jan;36(1):13.e11-13.e18. doi: 10.1016/j.urolonc.2017.08.023. Epub 2017 Sep 14.

PMID:
28919181
34.

Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion.

Bhindi B, Jiang H, Poyet C, Hermanns T, Hamilton RJ, Li K, Toi A, Finelli A, Zlotta AR, van der Kwast TH, Evans A, Fleshner NE, Kulkarni GS.

Urol Oncol. 2017 Oct;35(10):604.e17-604.e24. doi: 10.1016/j.urolonc.2017.06.044. Epub 2017 Aug 7.

PMID:
28781111
35.

Testosterone Responders to Continuous Androgen Deprivation Therapy Show Considerable Variations in Testosterone Levels on Followup: Implications for Clinical Practice.

Sayyid RK, Sayyid AK, Klaassen Z, Fadaak K, Goldberg H, Chandrasekar T, Ahmad A, Leao R, Perlis N, Chadwick K, Hamilton RJ, Kulkarni GS, Finelli A, Zlotta AR, Fleshner NE.

J Urol. 2018 Jan;199(1):251-256. doi: 10.1016/j.juro.2017.07.078. Epub 2017 Jul 25.

PMID:
28751266
36.

Metastatic renal cell carcinoma: Patterns and predictors of metastases-A contemporary population-based series.

Chandrasekar T, Klaassen Z, Goldberg H, Kulkarni GS, Hamilton RJ, Fleshner NE.

Urol Oncol. 2017 Nov;35(11):661.e7-661.e14. doi: 10.1016/j.urolonc.2017.06.060. Epub 2017 Jul 17.

PMID:
28728748
37.

The Association Between Vasectomy and Prostate Cancer: A Systematic Review and Meta-analysis.

Bhindi B, Wallis CJD, Nayan M, Farrell AM, Trost LW, Hamilton RJ, Kulkarni GS, Finelli A, Fleshner NE, Boorjian SA, Karnes RJ.

JAMA Intern Med. 2017 Sep 1;177(9):1273-1286. doi: 10.1001/jamainternmed.2017.2791.

38.

Psychological distress and lifestyle disruption in low-risk prostate cancer patients: Comparison between active surveillance and radical prostatectomy.

Matthew AG, Raz O, Currie KL, Louis AS, Jiang H, Davidson T, Fleshner NE, Finelli A, Trachtenberg J.

J Psychosoc Oncol. 2018 Mar-Apr;36(2):159-174. doi: 10.1080/07347332.2017.1342733. Epub 2017 Aug 8.

PMID:
28613997
39.

Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort.

Bhindi A, Bhindi B, Kulkarni GS, Hamilton RJ, Toi A, van der Kwast TH, Evans A, Zlotta AR, Finelli A, Fleshner NE.

Can Urol Assoc J. 2017 Jan-Feb;11(1-2):41-46. doi: 10.5489/cuaj.4031.

40.

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR.

J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14.

41.

Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.

Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek DH, Fleshner NE, Recker F, Kuk C, Olkhov-Mitsel E, Savas S, Hanna S, Juvet T, Hunter GA, Friedlander M, Li H, Chadwick K, Prassas I, Soosaipillai A, Randazzo M, Trachtenberg J, Toi A, Shiah YJ, Fraser M, van der Kwast T, Bristow RG, Bapat B, Diamandis EP, Boutros PC, Zlotta AR.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw258.

PMID:
28376164
42.

Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer.

Olkhov-Mitsel E, Savio AJ, Kron KJ, Pethe VV, Hermanns T, Fleshner NE, van Rhijn BW, van der Kwast TH, Zlotta AR, Bapat B.

Transl Oncol. 2017 Apr;10(2):168-177. doi: 10.1016/j.tranon.2017.01.001. Epub 2017 Feb 3.

43.

Variant Histology and Clinicopathological Features of Prostate Cancer in Men Younger than 50 Years Treated with Radical Prostatectomy.

Prendeville S, Nesbitt ME, Evans AJ, Fleshner NE, van der Kwast TH.

J Urol. 2017 Jul;198(1):79-85. doi: 10.1016/j.juro.2017.01.061. Epub 2017 Jan 24.

PMID:
28130102
44.

Genomic hallmarks of localized, non-indolent prostate cancer.

Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Berlin A, Lalonde E, Ahmed M, Trudel D, Luo X, Beck TA, Meng A, Zhang J, D'Costa A, Denroche RE, Kong H, Espiritu SM, Chua ML, Wong A, Chong T, Sam M, Johns J, Timms L, Buchner NB, Orain M, Picard V, Hovington H, Murison A, Kron K, Harding NJ, P'ng C, Houlahan KE, Chu KC, Lo B, Nguyen F, Li CH, Sun RX, de Borja R, Cooper CI, Hopkins JF, Govind SK, Fung C, Waggott D, Green J, Haider S, Chan-Seng-Yue MA, Jung E, Wang Z, Bergeron A, Dal Pra A, Lacombe L, Collins CC, Sahinalp C, Lupien M, Fleshner NE, He HH, Fradet Y, Tetu B, van der Kwast T, McPherson JD, Bristow RG, Boutros PC.

Nature. 2017 Jan 19;541(7637):359-364. doi: 10.1038/nature20788. Epub 2017 Jan 9.

PMID:
28068672
45.

Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking.

Poudineh M, Aldridge PM, Ahmed S, Green BJ, Kermanshah L, Nguyen V, Tu C, Mohamadi RM, Nam RK, Hansen A, Sridhar SS, Finelli A, Fleshner NE, Joshua AM, Sargent EH, Kelley SO.

Nat Nanotechnol. 2017 Mar;12(3):274-281. doi: 10.1038/nnano.2016.239. Epub 2016 Nov 21.

PMID:
27870841
46.

The uptake of active surveillance for the management of prostate cancer: A population-based analysis.

Richard PO, Alibhai SM, Panzarella T, Klotz L, Komisarenko M, Fleshner NE, Urbach D, Finelli A.

Can Urol Assoc J. 2016 Sep-Oct;10(9-10):E342-E346. Epub 2016 Oct 13. No abstract available.

47.

The uptake of active surveillance for the management of prostate cancer: A population-based analysis.

Richard PO, Alibhai SM, Panzarella T, Klotz L, Komisarenko M, Fleshner NE, Urbach D, Finelli A.

Can Urol Assoc J. 2016 Sep-Oct;10(9-10):333-338.

48.

A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.

Sayyid RK, Evans A, Hersey K, Maloni R, Hurtado-Coll A, Kulkarni G, Finelli A, Zlotta AR, Hamilton R, Gleave M, Fleshner NE.

Clin Cancer Res. 2017 Apr 15;23(8):1974-1980. doi: 10.1158/1078-0432.CCR-16-1790. Epub 2016 Oct 18.

49.

Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.

Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Venkateswaran V, Zlotta AR, Loblaw A, Fleshner NE, Klotz L, Vesprini D, Bapat B.

J Urol. 2017 Feb;197(2):335-341. doi: 10.1016/j.juro.2016.08.081. Epub 2016 Aug 18.

PMID:
27545574
50.

Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.

Alibhai SM, Timilshina N, Duff-Canning S, Breunis H, Tannock IF, Naglie G, Fleshner NE, Krahn MD, Warde P, Marzouk S, Tomlinson GA.

Cancer. 2017 Jan 1;123(2):237-244. doi: 10.1002/cncr.30320. Epub 2016 Sep 1.

Supplemental Content

Loading ...
Support Center